Comment on “Disease management: Atrial fibrillation and home monitoring”

Device-detected atrial fibrillation (AF) episodes predict poor clinical outcome regardless of symptoms.Potential benefits of remote monitoring are early arrhythmia detection and patient continuous monitoring.Several studies of device remote monitoring consistently demonstrated that AF represents the most common clinical alert and that detailed information on arrhythmia onset, duration, and burden as well as on the ventricular rate may be early available for clinical evaluation.Reaction time to AF alerts was very short in all series involving either pacemakers or defibrillators and action ability of AF alerts was very high.In the Home Guide Registry, in which 1650 patients were enrolled, AF was detected in 16.3% of patients and represented 36% of all cardiovascular events during the follow-up.Timely anticoagulation introduction in asymptomatic patients may impact on the stroke rate.According to the results of repeated Monte Carlo simulations based on a real population of 166 patients, daily monitoring may reduce the 2-year stroke risk by 9-18% with an absolute reduction of 0.2-0.6%,compared with conventional inter-visit intervals of 6-12 months.In the COMPAS trial, the incidence of hospitalizations for atrial arrhythmias and related stroke was significantly higher in the control group than in the remote monitoring group.Major questions will be addressed by the ongoing IMPACT trial in which a remote monitoring guided anticoagulation strategy based on AF detection will be compared with a physician-directed standard strategy.In patients with heart failure, AF early detection combined with other indexes may help prevent hospitalizations.